Second, because more than 50% of patients were diagnosed with metastatic HER2 positive breast cancer before pertuzumab was available, they were unable to receive pertuzumab which is now considered the standard therapy given with trastuzumab. This evidence concerns the gene ERBB2 and breast cancer.